Crinetics Pharmaceuticals Files 8-K

TL;DR

CRNX filed an 8-K, mostly exhibits. Nothing major to see here.

AI Summary

On October 8, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.

Why It Matters

This filing serves as a standard disclosure for Crinetics Pharmaceuticals, Inc., providing updates on financial statements and exhibits to the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, with no indication of significant new risks or events.

Key Players & Entities

• Crinetics Pharmaceuticals, Inc. (company) — Registrant
• October 8, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-38583 (identifier) — Commission File Number
• 26-3744114 (identifier) — IRS Employer Identification No.
• 6055 Lusk Boulevard (address) — Address of Principal Executive Offices
• San Diego (location) — City of Principal Executive Offices
• California (location) — State of Principal Executive Offices
• 92121 (zip_code) — Zip Code of Principal Executive Offices
• (858) 450-6464 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
• $50.00 — price to the public in this offering is $50.00 per share. The Underwriters have agreed
• $47.25 — he Underwriting Agreement at a price of $47.25 per share. The net proceeds to the Comp
• $472.0 m — fering are expected to be approximately $472.0 million, or approximately $542.9 million
• $542.9 million — mately $472.0 million, or approximately $542.9 million if the Option is exercised in full, aft

Filing Documents

• d857933d8k.htm (8-K) — 31KB
• d857933dex11.htm (EX-1.1) — 201KB
• d857933dex51.htm (EX-5.1) — 11KB
• d857933dex991.htm (EX-99.1) — 10KB
• d857933dex992.htm (EX-99.2) — 11KB
• g857933g1009112207236.jpg (GRAPHIC) — 3KB
• g857933g1009112325165.jpg (GRAPHIC) — 3KB
• g857933g1009112557891.jpg (GRAPHIC) — 2KB
• 0001193125-24-235275.txt ( ) — 463KB
• crnx-20241008.xsd (EX-101.SCH) — 3KB
• crnx-20241008_lab.xml (EX-101.LAB) — 17KB
• crnx-20241008_pre.xml (EX-101.PRE) — 11KB
• d857933d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this report are forward-looking statements. These forward-looking statements speak only as of the date of this report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, the risks and uncertainties described in the Company's periodic filings with the SEC. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated October 8, 2024, by and among Crinetics Pharmaceuticals, Inc. and Leerink Partners LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein 5.1 Opinion of Morrison & Foerster LLP 23.1 Consent of Morrison & Foerster LLP (included in Exhibit 5.1) 99.1 Press Release dated October 8, 2024 99.2 Press Release dated October 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: October 9, 2024 By: /s/ R. Scott Struthers, Ph.D. Name: R. Scott Struthers, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR